Injectable biocompatible composition

• US 10,500,154 B2
• Filed: 07/27/2010
• Issued: 12/10/2019
• Est. Priority Date: 01/28/2008
• Status: Active Grant

• Current Assignee: NMI Naturwissenschaftliches und Medizinisches Institut an an der Universität Tübingen. (NMI Natural and Medical Sciences Institute at the University TÜBINGEN)
• Original Assignee: NMI Naturwissenschaftliches und Medizinisches Institut an an der Universität Tübingen. (NMI Natural and Medical Sciences Institute at the University TÜBINGEN)
• Inventors: Mollenhauer, Juergen, Benz, Karin, Platz, Barbara, Wurst, Helmut, Stoop, Reinout
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US12/844,750
• Publication Number:
  US 20100322993A1
• Time in Patent Office: 3,423 Days
• Field of Search: None
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.

Claims

1. Method for treating cartilage disorders of a diseased or injured articular site in a mammal, said method comprising the steps of providing an injectable biocompatible composition based on a polymeric support which polymeric support comprises a hydrophilic polymer, wherein the hydrophilic polymer is polymerizable in situ to form a gel, wherein the hydrophilic polymer is serum albumin and wherein the serum albumin is functionalized by maleimide groups, wherein the serum albumin is cross-linked in situ via the groups via a thiol reaction, and injecting the composition into the articular site to be treated.

2. The method as claimed in claim 1, wherein the composition is used for replacing and/or for regenerating articular cartilage or intervertebral discs.

3. The method as claimed in claim 1, wherein the composition is used for introducing chondrocytes and/or mesenchymal stem cells into the articular site to be treated.

4. The method as claimed in claim 1, wherein the composition further comprises chondrocytes and/or mesenchymal stem cells.

5. The method as claimed in claim 1, wherein the composition further comprises a pharmacological agent, the pharmacological agent being selected from at least one of the following:

an antibiotic, an anti-inflammatory, a metabolism hormone, chondroprotectives, agents for gene therapy, growth hormones, differentiation or modulation factors, immunosuppressives, immunostimulatory substances, DMOAs, nucleic acids, apoptosis-inducing actives, adhesion-mediating actives, receptor agonists and receptor antagonists, or mixtures thereof.

6. The method as claimed in claim 1, wherein the composition further comprises hyaluronic acid.

7. The method as claimed in claim 1, wherein the composition further comprises a SH group-containing crosslinker.

8. The method as claimed in claim 7, wherein the SH group-containing crosslinker is selected from SH-modified dextran, SH-modified polyvinyl alcohol, SH-modified polyvinylpyrrolidone, or SH-modified polyethylene glycol.

9. Method for treating cartilage disorders of a diseased or injured articular site in a mammal, said method comprising the steps of providing an injectable biocompatible composition based on a polymeric support which polymeric support comprises a hydrophilic polymer, wherein the hydrophilic polymer is polymerizable in situ to form a gel, wherein the hydrophilic polymer is serum albumin or serum protein and wherein the serum albumin or serum protein is functionalized by maleimide, wherein the serum albumin or serum protein is cross-linked in situ via the groups via a thiol reaction, and wherein the composition further comprises a SH group-containing crosslinker, and injecting the composition into the articular site to be treated.